U.S. Patent and Trademark Office: U.S. DePARTMENT OF COMMERCE

_			Una	r me raq	SETWORK KOOLICION ACT OF 1993, I	to persons are required to respond to a con-	ECHOT OF BEGINNERSON GENESS IF BOTHLANDS & VALID COVID	COLINICA LIMITIDE		
Substitute for form 1449A/PTO						Complete if Known				
INFORMATION DI STATEMENT BY A	INFO	DRMAT	ION	DI	SCLOSURE	Application Number	To be assigned			
		Filing Date	February 27, 2004							
STATEMENT DI ATTECANI						First Named Inventor	Van Weeghel et al.			
						Group Art Unit	To be assigned			
(use as many sheets as necessary)				ets as	necessary)	Examiner Name	To be assigned			
	Sheet	1		of	2	Attorney Docket Number	2183-6372US			

U.S. PATENT DOCUMENTS					
		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Examiner Initials *	Cite No.	Number - Kind Code ² (if known)		Cited Document	Passages or Relevant Figures Appear
GG		US-5,962,234	10-05-1999	Golbus	
		US-			
		US-	·		
		US-			
		US-			
		US-	•		
		US-			· · · · · · · · · · · · · · · · · · ·
		US-			
		US-			
		US-			•
		US-			
		US-		<u> </u>	
		US-			
		US-			

Examiner	Cite No.1	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
Initials*		Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document		
		EP 0 971 233 A1	01-12-2000	Immunotech S.A.		
GG		WO 03/021275 A1	03-13-2003	IQ Corporation B.V.		
			-	· · · · · · · · · · · · · · · · · · ·		
			 			
			1	· · · · · · · · · · · · · · · · · · ·		

Examiner Signature /Gailene Gabel/ (11/27/2006) Cor	Date Considered 11/27/2006
---	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	<u> </u>	Complete if Known			
Substitute for form 1449A/PTO	•				
DIEGONA ACION DIG	OT OOTIDE	Application Number	To be assigned		
INFORMATION DIS		Filing Date	February 27, 2004		
STATEMENT BY AF	PPLICANT	First Named Inventor	van Weeghel et al.		
		Group Art Unit	To be assigned		
(use as many sheets as ne	cessary)	Examiner Name	To be assigned		
Sheet 2 of	2	Attorney Docket Number	2183-6372US		

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
GG		PCT International Search Report, PCT/NL02/00579, dated November 7, 2002.	
GG		PCT International Preliminary Examination Report, PCT/NL02/00579, dated July 16, 2003, 3 pages.	
GG		DAVIS, et al., Detection of fetal red cells in fetomaternal hemorrhage using a fetal hemoglobin monoclonal antibody by flow cytometry, Immunohematology, August 1998, pp. 749-56, Vol. 38.	
GG		BRADY et al., Expression of the human carbonic anhydrase I gene is activated late in fetal crythroid development and regulated by stage-specific trans-acting factors, British Journal of Haematology, 1990, pp. 135-42, Vol. 76.	

Examiner Signature	/Gailene Gabel/	(11/27/2006)	Date Considered	11/27/2006
2.8	L			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.